Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Ph...
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
About this item
Full title
Author / Creator
Publisher
Cheshire: Springer Healthcare
Journal title
Language
English
Formats
Publication information
Publisher
Cheshire: Springer Healthcare
Subjects
More information
Scope and Contents
Contents
Introduction
Efficacy and safety of the Janus kinase (JAK) inhibitor upadacitinib (UPA) was evaluated in patients with psoriatic arthritis (PsA) through week 104 of the ongoing long-term extension of the phase 3 trial SELECT-PsA 1.
Methods
Exploratory analyses of all primary and secondary endpoints (non-responder imputation and as observed...
Alternative Titles
Full title
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c0e6a38878a844d89c06b768c0e25ed2
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c0e6a38878a844d89c06b768c0e25ed2
Other Identifiers
ISSN
2198-6576
E-ISSN
2198-6584
DOI
10.1007/s40744-022-00499-w
